Pauls Dietrich John
- SEC CIK
- 0001760123
No open-market purchases or sales filed in the past year.
Current role at each company
- DMAC DiaMedica Therapeutics Inc.President & CEOas of Aug 12, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Pauls Dietrich John as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 26, 2023 (view filing) | Jun 23 | 3 days | Pauls Dietrich JohnPresident and CEO | PPurchaseVoting Common Shares, no par value per share | +12.8K | $3.91 | +$50.0K | +22.9%68.6K after | |
| Nov 16, 2022 (view filing) | Nov 16 | Same day | Pauls Dietrich JohnPresident and CEO | PPurchaseVoting Common Shares, no par value per share | +20.0K | $1.21 | +$24.2K | +55.9%55.8K after | |
| Aug 16, 2021 (view filing) | Aug 16 | Same day | Pauls Dietrich JohnPresident and CEO | PPurchaseVoting Common Shares, no par value per share | +5.00K | $3.14 | +$15.7K | +16.2%35.8K after |